Thrivent Financial For Lutherans Has $1.82 Million Position in Becton, Dickinson and Company (BDX)

Thrivent Financial For Lutherans boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 8.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,330 shares of the medical instruments supplier’s stock after purchasing an additional 715 shares during the quarter. Thrivent Financial For Lutherans’ holdings in Becton, Dickinson and were worth $1,822,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Janney Montgomery Scott LLC raised its stake in Becton, Dickinson and by 35.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after purchasing an additional 11,300 shares during the last quarter. Bessemer Group Inc. raised its stake in Becton, Dickinson and by 1.4% in the 2nd quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock valued at $190,827,000 after purchasing an additional 13,263 shares during the last quarter. Pictet Asset Management Ltd. raised its stake in Becton, Dickinson and by 9.3% in the 2nd quarter. Pictet Asset Management Ltd. now owns 246,404 shares of the medical instruments supplier’s stock valued at $46,627,000 after purchasing an additional 21,022 shares during the last quarter. Union Bankshares Corp raised its stake in Becton, Dickinson and by 1.7% in the 2nd quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock valued at $4,357,000 after purchasing an additional 381 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Becton, Dickinson and by 5.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock valued at $6,438,000 after purchasing an additional 1,819 shares during the last quarter. 87.12% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on the stock. Barclays PLC reissued an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $200.93.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period last year, the company posted $2.35 EPS. The business’s quarterly revenue was down 5.1% compared to the same quarter last year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were given a dividend of $0.73 per share. The ex-dividend date was Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.47%. Becton, Dickinson and’s payout ratio is presently 83.43%.

In other news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock valued at $15,242,688 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.

WARNING: “Thrivent Financial For Lutherans Has $1.82 Million Position in Becton, Dickinson and Company (BDX)” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/10/13/thrivent-financial-for-lutherans-has-1-82-million-position-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply